AUTL Autolus Therapeutics ADS

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Autolus Therapeutics to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announces that it will release its first quarter 2025 financial results and operational highlights before open of US markets on Thursday, May 8, 2025.

Management will host a conference call and webcast at 8:30 am EDT/13:30 pm BST to discuss the company’s financial results and provide a general business update. Conference call participants should pre-register using this to receive the dial-in numbers and a personal PIN, which are required to access the conference call.

A simultaneous audio webcast and replay will be accessible on the of Autolus’ website.

About Autolus Therapeutics plc

Autolus Therapeutics plc (Nasdaq: AUTL) is an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation T cell therapies for the treatment of cancer and autoimmune disease. Using a broad suite of proprietary and modular T cell programming technologies, Autolus is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and eliminate these cells. Autolus has an FDA approved product, AUCATZYL, and a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. For more information, please visit

Contact:  

Amanda Cray 

 

 

Olivia Manser 

8 

 



EN
22/04/2025

Underlying

AUTLAutolus Therapeutics ADS

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Autolus Therapeutics ADS

Jacob Mekhael
  • Jacob Mekhael
GLPG GALAPAGOS NV
AUTL Autolus Therape... ... (+3)

EHA abstracts Autolus, Galapagos, MaaT

The abstracts for presentations at EHA (12-15 June) became available yesterday during the day (here). While we may have to wait until the actual conference for the latest datasets, here in this note are some key takeaways for our coverage including updates from Autolus (long-term findings and predictors of sustained remission for Aucatzyl in r/r adult ALL, as well as age stratified outcomes), Galapagos (more data and follow up from its decentralised CAR-T program) and MaaT (additional data from ...

GLPG GALAPAGOS NV
AUTL AUTOLUS THERAPEUTICS ADS
MAAT MAAT PHARMA SA
05/15/25 May 15, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Presents Clinical Data Updates at the 2025 Europe...

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress LONDON, May 14, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces the online publication of three abstracts submitted to the European Hematology Association (EHA) Congress, to be held June 12-15, 2025, Milan, Italy. Autolus will have two oral and one poster presentation, which includes updated follow up from the FELIX ...

May 14, 2025 1 EN
Jacob Mekhael
  • Jacob Mekhael
AUTL Autolus Therape...

Autolus 1Q25 shows higher than expected Aucatzyl sales in r/r adult AL...

Yesterday before US market open, Autolus reported 1Q25 results with the highlight being the first Aucatzyl (CD19 CAR-T) sales in r/r adult ALL in the US ($ 9m), coming in above our expectations (1Q25 KBCSe $ 5m) and sending the stock up +10%. We see the stronger than expected initial demand as a good sign for the remainder of the launch. Seasonality remains to be seen, but if this momentum continues for the rest of FY25, our sales estimate of $ 43m will be within reach (BBG CSS $ 37m). We reiter...

AUTL AUTOLUS THERAPEUTICS ADS
05/09/25 May 9, 2025 1 EN
Hilde Van Boxstael ... (+7)
  • Hilde Van Boxstael
  • Jacob Mekhael
  • Lynn Hautekeete
  • Michiel Declercq
  • Thomas Vranken
  • Wim Hoste
  • Wim Lewi
PROX Proximus SA de ...
UCB UCB S.A. ... (+10)

Morning Notes : AED BB, BPOST BB, COFB BB, MONT BB, ONTEX BB, PROX BB,...

: AED BB, BPOST BB, COFB BB, MONT BB, ONTEX BB, PROX BB, UCB BB, VGP BB, AUTL US, ECMPA NA

PROX PROXIMUS SA DE DROIT PUBLIC
UCB UCB S.A.
COFB COFINIMMO SA
MONT MONTEA SCA
AED AEDIFICA SA
BPOST BPOST SA
ONTEX ONTEX GROUP N.V.
VGP VGP NV
AUTL AUTOLUS THERAPEUTICS ADS
ECMPA EUROCOMMERCIAL PROPERTIES NV
05/09/25 May 9, 2025 1 EN
 PRESS RELEASE
Free
AUTL Autolus Therape...

Autolus Therapeutics Reports First Quarter 2025 Financial Results and ...

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates Company reports Q1 2025 AUCATZYL® net product revenue of $9.0 millionU.K. Medicines and Healthcare products Regulatory Agency (MHRA) granted conditional marketing authorization for AUCATZYL® for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL)Encouraging preliminary data reported in Phase 1 CARLYSLE trial in systemic lupus erythematosus (SLE); planned Phase 2 pivotal clinical trial in lupus nephritis (LN) and Phase 1 clinical trial in pr...

May 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch